# Inflammatory Myopathies - Dermatomyositis and Polymyositis

## Introduction

The idiopathic inflammatory myopathies constitute a heterogeneous group of autoimmune diseases targeting skeletal muscle, and the modern understanding of these conditions has been fundamentally reshaped by the discovery and characterization of myositis-specific antibodies. Contemporary classification recognizes distinct clinicopathologic entities driven by these antibodies, including dermatomyositis, immune-mediated necrotizing myopathy, antisynthetase syndrome, and inclusion body myositis. The concept of polymyositis as a standalone entity is now seriously questioned, as many cases historically classified as polymyositis have been reclassified upon re-evaluation as immune-mediated necrotizing myopathy, antisynthetase syndrome, or inclusion body myositis when modern antibody panels and histopathologic criteria are applied.

## Classification and Updated Taxonomy

### 2017 EULAR/ACR Classification Criteria

The 2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies employ a probability-based scoring system incorporating clinical features and muscle biopsy findings. Variables include age at onset, the pattern of muscle weakness, skin manifestations, dysphagia, anti-Jo-1 antibody status, creatine kinase elevation, and specific muscle biopsy features. The criteria achieve a sensitivity of 93 percent and specificity of 88 percent when biopsy data are included, with somewhat lower performance of 87 percent sensitivity and 82 percent specificity when biopsy data are unavailable.

### MSA-Based Reclassification

The paradigm shift in inflammatory myopathy classification has been driven by the recognition that myositis-specific antibodies define clinically distinct phenotypes with predictable patterns of organ involvement, treatment response, and prognosis. Each MSA is typically mutually exclusive, meaning patients rarely harbor more than one MSA. These antibodies are now considered more informative than the traditional clinical classification for guiding prognosis and management decisions, and comprehensive MSA panel testing beyond anti-Jo-1 alone has become essential for accurate classification.

## Dermatomyositis

### Pathogenesis

The pathogenesis of dermatomyositis is fundamentally distinct from other inflammatory myopathies and involves complement-mediated microangiopathy. Deposition of the membrane attack complex C5b-9 on endomysial capillaries leads to capillary damage and ischemic injury to muscle fibers, producing the characteristic perifascicular atrophy in which muscle fibers at the periphery of fascicles show ischemic damage. A prominent type I interferon signature is detectable in both muscle and skin tissue, with overexpression of MxA protein serving as a histologic marker of this interferon activation. Plasmacytoid dendritic cell infiltration in affected tissues drives this interferon production.

### Cutaneous Manifestations

The cutaneous manifestations of dermatomyositis are distinctive and often diagnostic. The heliotrope rash, a violaceous discoloration of the upper eyelids with periorbital edema, is considered pathognomonic. Gottron papules, violaceous flat-topped papules overlying the metacarpophalangeal, proximal interphalangeal, and distal interphalangeal joints, as well as the elbows and knees, are also pathognomonic. The Gottron sign refers to a macular violaceous erythema in the same distribution without the raised papular quality. The V-sign describes erythema over the anterior neck and upper chest, while the shawl sign designates erythema over the upper back and shoulders. Mechanic's hands, characterized by hyperkeratotic, fissured skin on the radial and palmar aspects of the fingers, is more commonly seen in antisynthetase syndrome but can occur in dermatomyositis. The holster sign refers to poikiloderma on the lateral thighs. Nail fold changes including periungual erythema, dilated capillary loops, and cuticular overgrowth reflect the underlying microangiopathy. Calcinosis cutis is more common in juvenile dermatomyositis than adult disease. Panniculitis, presenting as subcutaneous inflammation, is an additional recognized manifestation.

### Clinically Amyopathic DM (CADM)

Clinically amyopathic dermatomyositis represents a critically important subtype in which patients exhibit classic dermatomyositis skin findings without clinically significant muscle weakness. Within this category, hypomyopathic dermatomyositis refers to patients with subclinical muscle involvement detectable only through mildly elevated creatine kinase or MRI changes, while amyopathic dermatomyositis refers to patients with no detectable muscle involvement for at least 6 months. The clinical significance of CADM is profoundly elevated when anti-MDA5 antibodies are present, as these patients carry a high risk of rapidly progressive interstitial lung disease that carries mortality rates of 30 to 50 percent.

### DM-Specific Antibodies

Each dermatomyositis-specific antibody defines a distinct clinical phenotype. Anti-Mi-2 is associated with classic dermatomyositis featuring prominent skin and muscle disease, carries a good prognosis, and typically responds well to standard immunosuppressive therapy. Anti-MDA5, also known as CADM-140, is associated with clinically amyopathic dermatomyositis, rapidly progressive interstitial lung disease, mucocutaneous ulceration, and panniculitis; it carries the highest mortality among DM-specific antibodies, with RP-ILD mortality of 30 to 50 percent, and is more prevalent in Asian populations. Anti-NXP2 is associated with calcinosis, particularly in juvenile dermatomyositis, with cancer association in adults and severe muscle disease. Anti-TIF1-gamma carries the strongest cancer association in adult dermatomyositis, with approximately 60 percent of positive patients over 40 years harboring an underlying malignancy, and is associated with classic skin disease. Anti-SAE is associated with an initially amyopathic presentation that evolves to include myopathy, with dysphagia being a common feature.

<image>A clinical dermatology-style illustration showing the characteristic cutaneous manifestations of dermatomyositis on a female figure. Show: (1) Heliotrope rash on upper eyelids with violaceous discoloration and periorbital edema, (2) Gottron papules as raised violaceous papules over the MCP and PIP joints of the hands, (3) V-sign erythema on the anterior neck and upper chest in a V-distribution, (4) Shawl sign erythema over the upper back and posterior shoulders, (5) Mechanic's hands with hyperkeratosis and fissuring on the lateral fingers, (6) Holster sign showing poikiloderma on the lateral thighs. Use annotations pointing to each finding with the clinical term. Include an inset showing nail fold capillary changes with dilated loops and periungual erythema.</image>

| MSA | Disease Association | Key Clinical Features | Cancer Risk | ILD Risk | Prognosis |
|-----|--------------------|-----------------------|-------------|---------|-----------|
| Anti-Mi-2 | Classic DM | Prominent skin rash + muscle disease | Low | Low | Good; responds well to standard therapy |
| Anti-MDA5 (CADM-140) | CADM / amyopathic DM | Mucocutaneous ulcers, panniculitis, **RP-ILD** | Low | **Very high** (30–50% mortality from RP-ILD) | Poor without aggressive treatment |
| Anti-TIF1-gamma | DM (adults >40) | Classic skin disease; **~60% have underlying malignancy** | **Highest** | Low | Depends on cancer detection |
| Anti-NXP2 | DM (juvenile > adult) | Calcinosis (juvenile), severe myopathy; cancer in adults | Moderate (adults) | Low | Variable |
| Anti-SAE | DM | Initially amyopathic → evolves to myopathy; dysphagia | Low | Low-moderate | Moderate |
| Anti-Jo-1 | Antisynthetase syndrome | Classic triad: myositis + ILD + arthritis; mechanic's hands | Low | Moderate | Moderate |
| Anti-PL-7, PL-12 | Antisynthetase (non-Jo-1) | **ILD-predominant** with minimal myositis | Low | High | Depends on ILD severity |
| Anti-SRP | IMNM | Severe refractory myopathy; CK often >10,000; cardiac involvement | Low | Low | Poor without aggressive multi-drug therapy |
| Anti-HMGCR | IMNM | Statin-associated (but can occur without statins); high CK | Low | Low | Treatment-refractory; often needs IVIG |
| Anti-cN1A | IBM | Finger flexor + quadriceps weakness; dysphagia; age >50 | Low | Low | **Does not respond to immunosuppression** |

## Antisynthetase Syndrome

### Clinical Features (Triad)

Antisynthetase syndrome is defined by the classic triad of myositis, interstitial lung disease, and inflammatory arthritis, the latter being non-erosive and symmetric. Additional features include Raynaud phenomenon, mechanic's hands, and fever. The prognosis of antisynthetase syndrome is predominantly determined by the severity and course of the interstitial lung disease, making pulmonary assessment a cornerstone of management.

### Antisynthetase Antibodies

Anti-Jo-1, directed against histidyl-tRNA synthetase, is the most common antisynthetase antibody, found in approximately 20 to 30 percent of patients with idiopathic inflammatory myopathy, and is associated with the classic clinical triad and a moderate prognosis. The non-Jo-1 antisynthetase antibodies, including anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS, anti-Zo, and anti-Ha, tend to present with an ILD-predominant phenotype with less prominent myositis. Anti-PL-7 and anti-PL-12 are particularly associated with ILD-predominant disease and minimal myositis. These non-Jo-1 antibodies are often missed when only anti-Jo-1 testing is performed, underscoring the importance of ordering extended myositis-specific antibody panels.

### ILD in Antisynthetase Syndrome

The ILD associated with antisynthetase syndrome most commonly presents with a nonspecific interstitial pneumonia pattern, though organizing pneumonia and usual interstitial pneumonia patterns also occur. ILD may be the presenting feature of antisynthetase syndrome, emerging before any detectable myositis. The onset can be acute or subacute, and progression can be rapid, necessitating vigilant monitoring. Treatment typically involves glucocorticoids combined with immunosuppressive therapy, with mycophenolate mofetil, azathioprine, tacrolimus, and rituximab being the most commonly used agents.

## Immune-Mediated Necrotizing Myopathy (IMNM)

### Pathology

The muscle biopsy in immune-mediated necrotizing myopathy reveals a distinctive pattern of necrotic and regenerating fibers with minimal inflammatory infiltrate. The infiltrate that is present is predominantly composed of macrophages rather than lymphocytes, and complement C5b-9 is deposited on the sarcolemma of non-necrotic fibers. This histopathologic profile is distinct from dermatomyositis, which shows perifascicular atrophy, and from the endomysial CD8-positive T cell invasion pattern associated with older concepts of polymyositis.

### IMNM-Specific Antibodies

Anti-SRP antibodies are associated with severe, treatment-refractory myopathy with creatine kinase levels often exceeding 10,000, cardiac involvement, and a poor prognosis without aggressive treatment. ILD is less common than in antisynthetase syndrome. Anti-HMGCR antibodies are found in patients with statin exposure, though the myopathy can occur without prior statin use. The CK is markedly elevated, and the myopathy tends to be treatment-refractory, often requiring intravenous immunoglobulin for adequate control. Seronegative IMNM accounts for approximately 30 percent of IMNM cases and shows overlap with cancer-associated myopathy.

### Management of IMNM

Aggressive immunosuppression is required for IMNM, typically involving multimodal therapy. Anti-SRP IMNM is managed with glucocorticoids, intravenous immunoglobulin, and rituximab or mycophenolate mofetil, with many patients requiring maintenance IVIG. Anti-HMGCR IMNM requires statin discontinuation followed by glucocorticoids and IVIG, with the addition of methotrexate or rituximab for refractory cases. Normalization of creatine kinase levels correlates with strength recovery and serves as a useful biomarker for treatment response.

## Inclusion Body Myositis (IBM)

### Clinical Features

Inclusion body myositis is the most common acquired myopathy in patients over 50 years of age, with a male-to-female predominance of approximately 3 to 1. The onset is insidious, and the disease is often misdiagnosed as polymyositis for years before the correct diagnosis is established. The pattern of weakness is highly distinctive, involving asymmetric weakness of the finger flexors, particularly the flexor digitorum profundus, and the knee extensors, specifically the quadriceps. Dysphagia occurs in 40 to 60 percent of patients. The cardinal clinical feature that distinguishes IBM from other idiopathic inflammatory myopathies is that it does not respond to immunosuppressive therapy.

### Diagnosis

Creatine kinase is only mildly elevated in IBM, typically less than 10 times the upper limit of normal. Electromyography reveals an irritable myopathy with the unusual combination of mixed myopathic and neurogenic features. Muscle biopsy demonstrates the coexistence of endomysial CD8-positive T cell invasion of non-necrotic fibers, rimmed vacuoles, congophilic amyloid deposits, and tubulofilamentous inclusions visible on electron microscopy. Anti-cN1A antibodies, directed against cytosolic 5-prime-nucleotidase 1A, have a sensitivity of approximately 60 percent but are not highly specific and cannot be relied upon as a sole diagnostic marker.

## Diagnostic Evaluation

### Laboratory

Creatine kinase is the primary serum biomarker for inflammatory myopathy and may exceed 50 times the upper limit of normal in IMNM, though a normal CK does not exclude dermatomyositis, particularly the amyopathic variant. Aldolase is an alternative muscle enzyme that may be elevated even when CK is normal in some patients with dermatomyositis or antisynthetase syndrome. Transaminases including LDH, AST, and ALT are frequently elevated from their muscle isoforms rather than from hepatic origin, a distinction that is critically important to recognize before pursuing hepatic workup. ESR and CRP are often normal in myositis but may be elevated in antisynthetase syndrome. A comprehensive myositis-specific antibody panel extending beyond anti-Jo-1 is essential for accurate classification and prognostication.

### Imaging

MRI using T2-weighted and STIR sequences is the primary imaging modality for inflammatory myopathy, demonstrating muscle edema in active myositis and fatty replacement in chronic damage. MRI is valuable for guiding biopsy site selection, helping to avoid sampling end-stage or normal muscle that would yield non-diagnostic results. Thigh MRI is the most commonly used anatomic focus. High-resolution CT of the chest should be performed at baseline in all patients with IIM to screen for interstitial lung disease.

### Electromyography

Electromyography reveals an irritable myopathy characterized by short-duration, low-amplitude, polyphasic motor unit potentials along with fibrillation potentials and positive sharp waves. Nerve conduction studies are normal, which helps exclude neurogenic causes such as amyotrophic lateral sclerosis and neuropathy.

### Muscle Biopsy

Muscle biopsy remains the gold standard for definitive diagnosis and classification of inflammatory myopathy. In dermatomyositis, the characteristic findings are perifascicular atrophy, C5b-9 deposition on endomysial capillaries, and perivascular inflammation. In immune-mediated necrotizing myopathy, the biopsy shows necrosis and regeneration of muscle fibers, macrophage predominance, C5b-9 deposition on the fiber sarcolemma, and minimal inflammatory infiltrate. In inclusion body myositis, the hallmark findings include endomysial CD8-positive T cell infiltration, rimmed vacuoles, amyloid deposits, and tubulofilamentous inclusions. The pattern traditionally ascribed to polymyositis shows endomysial CD8-positive T cells invading non-necrotic muscle fibers with MHC class I upregulation.

<image>A four-panel histopathological comparison of muscle biopsy findings in the four major idiopathic inflammatory myopathies. Panel A (Dermatomyositis): Show perifascicular atrophy with pale, atrophic fibers at the periphery of muscle fascicles, perivascular and perimysial CD4+ T cell and B cell inflammation, and C5b-9 deposition on capillaries. Panel B (Antisynthetase syndrome): Perifascicular necrosis with fragmentation of perifascicular fibers, perimysial connective tissue fragmentation and alkaline phosphatase positivity. Panel C (Immune-mediated necrotizing myopathy): Scattered necrotic fibers undergoing phagocytosis by macrophages, regenerating fibers (basophilic), minimal inflammatory infiltrate, C5b-9 on sarcolemma. Panel D (Inclusion body myositis): Endomysial CD8+ T cells invading non-necrotic fibers, rimmed vacuoles (blue-rimmed on trichrome), and congophilic amyloid deposits. Label all key features in each panel.</image>

## Management

### Dermatomyositis and Antisynthetase Syndrome

Induction therapy begins with prednisone at 1 milligram per kilogram daily, with a maximum of 80 milligrams, tapered over 6 to 12 months. Steroid-sparing agents should be initiated concurrently with induction therapy. Methotrexate at 15 to 25 milligrams weekly is the first-line choice for muscle-predominant disease. Azathioprine at 2 to 3 milligrams per kilogram daily serves as an alternative, with particular utility in ILD. Mycophenolate mofetil at 2 to 3 grams daily is preferred for ILD-predominant disease. Tacrolimus at 2 to 4 milligrams daily has demonstrated effectiveness for ILD, especially in antisynthetase syndrome, with substantial supporting data from Japanese studies.

For refractory disease, intravenous immunoglobulin has been established as an effective therapy through the ProDERM trial, in which IVIG (Octagam 10%) improved the total improvement score compared to placebo in dermatomyositis, leading to FDA approval for DM in 2021. Rituximab was evaluated in the RIM trial, which was technically negative in that it did not meet its primary endpoint at 8 weeks; however, 83 percent of patients improved by 44 weeks, and rituximab is widely used and effective in clinical practice. For severe disease, combination regimens incorporating glucocorticoids, methotrexate, and either IVIG or rituximab are employed.

The management of anti-MDA5-positive rapidly progressive ILD constitutes a medical emergency. Triple therapy with glucocorticoids, tacrolimus, and intravenous cyclophosphamide, or alternatively glucocorticoids with cyclophosphamide and rituximab, is used in an attempt to arrest the fulminant pulmonary course. Plasma exchange and JAK inhibitors such as tofacitinib are under investigation for this devastating complication, which carries mortality rates of 30 to 50 percent.

### Cancer Screening

Dermatomyositis carries the strongest cancer association among the idiopathic inflammatory myopathies, with the risk being highest in the first 3 years after diagnosis. Anti-TIF1-gamma antibody positivity in adults over 40 years is associated with an approximately 60 percent prevalence of underlying malignancy, with the most common cancers being breast, ovarian, lung, gastrointestinal, and lymphoma. Anti-NXP2 also carries a cancer association in adults. Cancer screening should include CT of the chest, abdomen, and pelvis, along with age-appropriate cancer screening such as mammography, colonoscopy, and cervical cytology, and PET-CT when clinical suspicion is high. Screening should be repeated annually for 3 to 5 years after the initial diagnosis of inflammatory myopathy.

## Key Clinical Pearls

- Anti-MDA5 positive CADM with rapidly progressive ILD is a medical emergency with 30-50% mortality; requires immediate aggressive treatment
- Anti-TIF1-gamma antibody in adults >40 should trigger comprehensive malignancy screening for 3-5 years
- "Polymyositis" is overdiagnosed; most cases are actually IMNM, antisynthetase syndrome, or IBM on re-evaluation
- IBM does not respond to immunosuppression; avoid prolonged futile treatment with steroids
- Elevated transaminases in IIM are often from muscle, not liver; check CK before pursuing hepatic workup
- Myositis-specific antibody panels beyond anti-Jo-1 are essential for accurate classification and prognostication

## References
1. Lundberg IE, et al. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. Arthritis Rheumatol. 2017;69(12):2271-2282.
2. Aggarwal R, et al. Trial of intravenous immune globulin in dermatomyositis (ProDERM). N Engl J Med. 2022;387(14):1264-1278.
3. Allenbach Y, et al. Integrated classification of inflammatory myopathies. Neuropathol Appl Neurobiol. 2017;43(1):62-81.
4. Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016;280(1):8-23.
5. Oddis CV, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis (RIM). Arthritis Rheum. 2013;65(2):314-324.